About Aqilion
Aqilion is a biotech company that focuses on developing innovative new treatments for diseases caused by chronic inflammation and dysfunctional immune reactions such as autoimmune diseases.
We identify innovative ideas that could potentially lead to new medications and refine them into commercially interesting projects. The innovation approach is based on solid scientific grounds, in disease areas where we, with reasonable assumptions, can understand the underlying biology, clinical relevance of the mechanism, potential patient benefit and the likelihood for finding a partner.
The company is mainly active in the early phases of drug discovery, from idea to proof-of-concept in clinical trials. Aqilion executes it’s development programs in a partly virtual organization in close collaboration with selected partners, with specific expertise in drug development.
AQILION AB (publ) is a Swedish public limited company headquartered in Helsingborg, Sweden.
